Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 03, 2008. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and contains no financial performance data.
Material Changes
The filing details the Company's issued share capital as of October 31, 2008:
- Total issued Ordinary shares: 5,691,451,596 (25p each).
- Shares held in Treasury: 474,194,158.
- Total voting rights: 5,217,257,438.
No material changes to financial performance or operations are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital figures for shareholder notification purposes.
Investor Verification Points
- Verify the total number of voting rights (5,217,257,438) for compliance with Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) to calculate the correct denominator for interest notifications.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance data.